Staff scientists

Photo of Atsuko Ogino, MD, PhD

Atsuko Ogino, MD, PhD, (Atsuko_Ogino@dfci.harvard.edu) explores the relationship between tumor heterogeneity, pluripotency, and drug-resistance. Her ongoing studies, focusing primarily on small-cell lung cancer transformation and oncogenic NRAS, utilize patient-derived lung cancer cell lines and patient-derived xenograft (PDX) models.

Photo of Ciric To, PhD

Ciric To, PhD, (CiricC_To@dfci.harvard.edu) pursues the development of non-conventional approaches to target EGFR, such as highly specific allosteric inhibitors and PROTACs in NSCLC models. Her goal is to simultaneously generate and/or identify important resistance-imparting mechanisms that emerge following treatment with allosteric inhibitors.